Finally, our results also demonstrated that treatments of IGF1R inhibitor PPP in HCC cells abolished PSPC1-activated IGF1R gene expression, downstream FAK/Src and AKT, as well as cell motility. This evidence concerns the gene IGF1R and hepatocellular carcinoma.